Eli Lilly’s Jaypirca Receives the US FDA Approval for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma ( CLL/SLL )
Shots:
- The approval was based on the P-I/II (BRUIN) study evaluating the efficacy of Jayprica (200mg; QD) for the treatment of patients (n=108) with CLL/SLL who were previously treated with at least two prior lines of therapy excl. CNS involvement or recent HSCT
- The result showed ORR & partial response of 72% whereas the time to response was 3.7 mos. & mDoR was 12.2 mos. Additionally, ARs led to dose reductions in 3.6%, treatment interruption in 42%, & permanent discontinuation in 9%
- Jaypirca (pirtobrutinib) approved under the FDA's Accelerated Approval is a reversible BTK inhibitor, targeting B-cell cancers like mantle cell lymphoma and CLL/SLL
Ref: PR Newswire | Image: Eli Lilly
Related News:- Eli Lilly’s Zepbound (tirzepatide) Receives the US FDA’s Approval as a Treatment for Obesity or Overweight
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
